Doing (IP) Business in BRIC Countries

Similar documents
On becoming and being a patent attorney

Foreign Filing Strategies - Considerations in Protecting Your Patents Globally

Lawrence T. Welch Eli Lilly and Company INDUSTRY COMMENTS

Observations from Pharma

An overview of India's approach to key IP issues at home and abroad. Dr. Bona Muzaka King s College London

Carnegie Endowment for International Peace

Flexibilities in the Patent System

ROLE OF INTELLECTUAL PROPERTY RIGHTS IN DEVELOPING COUNTRIES -ASHWINI SANDU.

Freedom to Operate (FTO) from a large company s perspective

TRIPS and Access to Medicines. The Story so far

TRAINING SEMINAR PHARMACEUTICALS AND INTELLECTUAL PROPERTY ACCESS TO MEDICINE: Exploitation of pharmaceutical patents: compulsory licences SESSION 4

Patenting Strategies. The First Steps. Patenting Strategies / Bernhard Nussbaumer, 12/17/2009 1

Intellectual Property

TRIPS and Access to Medicines. WR Briefing

5 th Annual Pharma IPR Conference 2016

Exhaustive Training module for new Patent examiners

IP Strategies to Enhance Competitiveness: India s Experience

INTEGRATING INNOVATION AND CREATIVITY INTO NATIONAL POLICIES AND STRATEGIES OGADA T.

Common Pools in Aquaculture Sui Generis and Other Options for Benefit Sharing

TRIPs & PATENTS. In 1899, Mr. Charles H. Duell, Director of US Patent office said Everything that can be invented, has (already) been invented.

Issues at the Intersection of IP and Competition Policy

Alternatives to the patent system used to support R&D Efforts. James Love WIPO Expert Forum on International Technology Transfer February 17, 2015

The Green Economy: Trade and Sustainable Development Implications. From Rio to Rio:Technology Transfer, Innovation and Intellectual Property

Why patents DO matter to YOUR business

Draft for consideration

The Standardization and the Patent Issue in Telemedicine

The role of IP in economic development: the case of China

Intellectual Property and Genetic Resources: Relationship with Relevant International Instruments

Nitya Nanda. The Energy and Resources Institute (TERI)

Dr. Biswajit Dhar Professor, Jawaharlal Nehru University, India and Member DA9 Advisory Board

Chapter: Science, Technology, and Society

Bayer aligns organization with Life Science businesses

strong patents, weak patents and evergreening: should patents for drugs be challenged more often? Giancarlo Del Corno Studio Legale Sena e Tarchini

Intellectual Property and Technology Transfer

IP for Development Indian Approach

Submission to the Productivity Commission inquiry into Intellectual Property Arrangements

Key Strategies for Your IP Portfolio

Flexibilities in the Patent System

State of Licensing 2011 Update

Access to Technology in the Post-2015 Development Agenda. Alessandra Casazza Policy Advisor UNDP Asia-Pacific Regional Center

Subregional Seminar on the Legal Protection of Biotechnology and Genetic Resources Banska Bystrica, May 2 and 3, Access and Benefit Sharing

WHO workshop on IP and Vaccines. Geneva 19 th -20 th April Introduction to the IP issues Christopher Garrison Consultant to WHO

Standing Committee on the Law of Patents

WORLD TRADE ORGANIZATION

An Essential Health and Biomedical R&D Treaty

International Patent Regime. Michael Blakeney

A Brief History of IP & Patents: Drawing Lessons from the Past

Functionality of the Nagoya ABS Protocol with a view to AnGR and a side-look to Anti- Conterfeiting Trade Agreement (ACTA)

5/30/2018. Prof. Steven S. Saliterman Department of Biomedical Engineering, University of Minnesota

10 YEARS OF GENERIC MEDICINES IN BRASIL. Growth Earnings Challenges

Multilateral negotiations on IP - Traditional Knowledge and Genetic resources

Social returns to direct private innovation support: the patent system

Regional Seminar on the Effective Implementation and Use of Several Patent-Related Flexibilities

Standing Committee on the Law of Patents Twenty-Sixth Session

T F White Collar, Compliance and Investigations > Anti-Corruption Compliance and Investigations >

Technology Commercialization Primer: Understanding the Basics. Leza Besemann

Intergovernmental Committee on Intellectual Property and Genetic Resources, Traditional Knowledge and Folklore

BIOPIRACY: FACT OR FICTION? INTERNATIONAL TREATY NEGOTIATIONS COULD AFFECT YOUR IP RIGHTS AND YOUR BOTTOM LINE

South South Cooperation on IP and Development: Approaching IP Governance from a Development Perspective

Influences of Digital Transformation on Freedom to Operate Processes in the Chemical Industry

INDIA Market Projections and Developments

CRIRSCO and evolving international accounting standards: IFRSs

Patent Office. Patent Administration And Certificate section And Controlling group. Patent. Licensing and Opposition. Group. PCT receiving office

Patent Filing Strategy in Hong Kong

Patent application strategy when, where, what to file?

International IP. Prof. Eric E. Johnson. General Principles

UNCTAD Ad Hoc Expert Meeting on the Green Economy: Trade and Sustainable Development Implications November

HIV and co-infection medicines

UNCITRAL Third International Colloquium on Secured Transactions Session on Contractual Guide on IP Licensing (Vienna, March 3, 2010)

Prof. Steven S. Saliterman. Department of Biomedical Engineering, University of Minnesota

Research Patents in Biotech SMEs

Promotion of Innovation: Usefulness and Value of Patent Information for Public and Private Sectors

Patenting trends in Indian pharmaceutical industry

Patents in an Environment of Global Collaboration

Singapore IP Hub. Tan Yih San, Chief Executive, IPOS. January Copyright IPOS All intellectual property reserved.

Valerie S. Gaydos Angel Investor President, Capital Growth, Inc. How Proposed Patent Reform Increases Risk for Start-Up Investors

Intellectual Property Rights and Development CARLOS M. CORREA

The Usefulness of Patent Information for the Promotion of Innovation

Clarity of thought: telling Congress how to improve 101

Public Research and Intellectual Property Rights

Intellectual Property & Technology Transfer

Globalizing IPR Protection: How Important Might RTAs Be?

WIPO REGIONAL SEMINAR ON SUPPORT SERVICES FOR INVENTORS, VALUATION AND COMMERCIALIZATION OF INVENTIONS AND RESEARCH RESULTS

IP Issues in Global Health. Lenias Hwenda, Ph.D. The African Group, WHO/UNAIDS Geneva. Trondheim, 27 September 2012

IP Reserch and Use of IP Case Studies for Educational Purposes: Views and Challenges Geneva, April 26-29, 29, 2011

The high cost of standardization How to reward innovators

TRIPS-plus How FTAs and other bilateral treaties impose intellectual property rights on life in developing countries

BIPF Munich. South Africa Enforcement of Pharmaceutical Patents and the New Draft IP Policy

Pharmaceutical Patents in India - Seminar on Global l Best IPR Practices Indo American Chamber of Commerce

Identifying and Managing Joint Inventions

RECENT DEVELOPMENTS IN THE IMEC IP BUSINESS

2018 1Q IR PRESENTATION

WORLD TRADE ORGANIZATION ADVANCED COURSE. WIPO-WTO/ADV/ACAD/13/INF1.PROV ORIGINAL: English DATE: XXXX

Does the Increase of Patent in China Means the Improvement of Innovation Capability?

WORLD TRADE ORGANIZATION

Innovation, Creativity, and Intellectual Property Rights

Changing role of the State in Innovative Activity The Indian Experience. Sunil Mani

Regional Seminar for Certain African Countries on the Implementation and Use of Several Patent-Related Flexibilities

Building a Competitive Edge: Protecting Inventions by Patents and Utility Models

Sustainable development

Transcription:

Doing (IP) Business in BRIC Countries WIPO Conference, November 2016 Dr. Joerg Thomaier, Head of IP Bayer Group

Agenda A Public Contract called Patent Law Brazil Russia India China BRIC Comparison Summary Page 2

A Public Contract called Patent Law 1. The Contract Quid pro quo Deal between the public and the innovator: Quid: The inventor/patentee shares the invention with the public by disclosing it and therefore enabling and fostering further development and progress of humanity Quo: The public grants the inventor/patentee a 20 year exclusivity/legal monopoly to recoup the investments and to earn the deserved fruits of his work Page 3

A Public Contract called Patent Law 2. Effect of the Contract in the past Innovators spent a lot of money and efforts to achieve new and inventive solutions for the worlds problems, i.e. : - new materials to build things you couldn't build before i.e. aircrafts, solar panels etc - New drugs to cure uncurable diseases, e. g. pneumonia, life threating wound infections and a lot more - New pest controls and/or fertilizers to enhance farming productivity to help feeding people Thereby building upon each others inventions. Page 4

Brazil Double Examination of Patents in Pharma through ANVISA Political drift against Patents Protectionism Reliability/Speed of courts Thinking about CL (Compulsory Licenses) outside of TRIPS (not happened yet) Protection of Plant inventions difficult Page 5

Russia Not a lot of experience yet Protectionism Reliability of courts post communist heritage Difficult environment Page 6

India Section 3 d Multiple revocation opportunities Political drift against Patents Protectionism i.e. Generic industry Questionable use of CL Regime - outside of TRIPS? Slow and expensive court proceedings Reliability of courts Difficult environment Page 7

China Biological examples Stuck with original examples Relative quick examination procedure Fair trial (from Bayer/German Perspective) Political drift pro Patents Protectionism Reliability of courts, structured and quick proceedings Administrative enforcement at trade fairs! Page 8

BRIC Comparison Patent Law Brazil Russia India China Court Proceedings (Speed and Costs) Compulsory Licenses Reliability of Courts Protectionism Page 9

Summary and Conclusion From Bayer s perspective all BRIC countries still have room for improvement in IP in different aspects while China for the time being seem to be ahead. Too much protectionism still in place. Cultural differences and different heritages still leave difficult environments also in IP. Predictability of political decisions resp. their sustainability are also a bit of a concern. Page 10

Forward-Looking Statements This website/release/presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer s public reports which are available on the Bayer website at http://www.bayer.com/. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. Page 11

Thank you!